China SXT Pharmaceuticals, Inc.
SXTC
$2.45
$0.01040.43%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 414.70K | 414.70K | 494.50K | 494.50K | 469.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 414.70K | 414.70K | 494.50K | 494.50K | 469.80K |
| Cost of Revenue | 347.40K | 347.40K | 361.60K | 361.60K | 325.60K |
| Gross Profit | 67.40K | 67.40K | 132.80K | 132.80K | 144.20K |
| SG&A Expenses | 386.50K | 386.50K | -3.50M | -3.50M | 4.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 733.90K | 733.90K | -3.13M | -3.13M | 5.14M |
| Operating Income | -319.10K | -319.10K | 3.63M | 3.63M | -4.67M |
| Income Before Tax | -401.30K | -401.30K | 3.30M | 3.30M | -4.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -401.30K | -401.30K | 3.30M | 3.30M | -4.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -401.30K | -401.30K | 3.30M | 3.30M | -4.85M |
| EBIT | -319.10K | -319.10K | 3.63M | 3.63M | -4.67M |
| EBITDA | -284.90K | -284.90K | 3.68M | 3.68M | -4.62M |
| EPS Basic | -0.99 | -0.99 | 21.40 | 21.40 | -77.34 |
| Normalized Basic EPS | -0.62 | -0.62 | 14.23 | 14.23 | -48.34 |
| EPS Diluted | -0.99 | -0.99 | 21.40 | 21.40 | -77.34 |
| Normalized Diluted EPS | -0.62 | -0.62 | 14.23 | 14.23 | -48.34 |
| Average Basic Shares Outstanding | 403.90K | 403.90K | 154.20K | 154.20K | 62.70K |
| Average Diluted Shares Outstanding | 403.90K | 403.90K | 154.20K | 154.20K | 62.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
